Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
28.07%
Operating Margin
19.99%
Net Margin
16.41%
Efficiency Metrics
Revenue per Expense Ratio
1.25
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
35.78%
Income Tax Rate
2.79%
EPS
1.1900000000
Balance Sheet Analysis
Current Ratio
2.26
Cash Ratio
1.48
Working Capital
$176.68M
Debt to Equity
0.78
Debt to Assets
39.85%
Equity Ratio
51.01%
Cash Flow Analysis
Operating Cash Flow Ratio
28.23%
Free Cash Flow Ratio
20.53%
CapEx to Revenue
7.70%
Dividends Paid
$169.99M
Stock Buybacks
$4.30M
Total Shareholder Returns
$174.29M
Cash Position Change
81.79%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 1.31%
Detailed Growth Metrics
Core Performance
Revenue
16.26%
Net Income
62.03%
EPS
63.01%
Operating Income
27.43%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
18.73%
Operating Cash Flow
10.84%
Free Cash Flow
176.81%
Balance Sheet Health
Assets
-3.74%
Debt
-9.36%
Book Value per Share
-2.60%
Inventory
30.71%
Shareholder Returns
Dividends per Share
1.31%
Shares Outstanding
1.26%
Long Term Trends
3Y Revenue/Share
11.23%
5Y Revenue/Share
12.89%
3Y Dividend/Share
5.03%
5Y Dividend/Share
8.31%